Melioidosis and Burkholderia pseudomallei : progress in epidemiology, diagnosis, treatment and vaccination.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
pubmed:
10
8
2022
medline:
10
11
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
Melioidosis and its causative bacterium Burkholderia pseudomallei are being found in unexpected locations and bacterial genotyping is providing new insights into global spread and where and how individuals are being infected. This review summarizes recent studies covering the epidemiology, diagnosis, treatment, and prevention of melioidosis. Whole-genome sequencing of B. pseudomallei from patients and environmental sampling is informing the phylogeography of B. pseudomallei at regional, continental, and global levels, while also defining the epidemiology for individual cases. The situation in Africa remains the most unresolved, while the evolving story of B. pseudomallei in the Americas may establish that B. pseudomallei is endemic in parts of southern USA. Guidelines for diagnosis and treatment of melioidosis are well established, and published mortality has decreased from 50% or higher to 10% or lower in some countries but access to laboratory and therapeutic resources are not available or are extremely limited in many melioidosis-endemic regions. The enormous clinical diversity of melioidosis and the complexities of laboratory diagnosis and of treatment make it a sentinel disease for highlighting the continuing global disparities in access to and provision of healthcare.
Identifiants
pubmed: 35942848
doi: 10.1097/QCO.0000000000000869
pii: 00001432-202212000-00005
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
517-523Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Dance DAB. Melioidosis. Rev Med Microbiol 1990; 1:143–150.
White NJ. Melioidosis. Lancet 2003; 361:1715–1722.
Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18:383–416.
Limmathurotsakul D, Peacock SJ. Melioidosis: a clinical overview. Brit Med Bull 2011; 99:125–139.
Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. New Engl J Med 2012; 367:1035–1044.
Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Sem Resp Crit Care Med 2015; 36:111–125.
Wiersinga WJ, Virk HS, Torres AG, et al. Melioidosis. Nature Rev Dis Prim 2018; 4:17107.
Gassiep I, Armstrong M, Norton R. Human melioidosis. Clin Microbiol Rev 2020; 33:e00006–e00019.
Birnie E, Biemond JJ, Wiersinga WJ. Drivers of melioidosis endemicity: epidemiological transition, zoonosis, and climate change. Curr Opin Infect Dis 2022; 35:196–204.
Limmathurotsakul D, Golding N, Dance DAB, et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nature Microbiol 2016; 1:15008.
Warner J, Rush C. Tropical fever in remote tropics: tuberculosis or melioidosis, it depends on the lab. Microbiology Australia 2021; 42:173–178.
Birnie E, James A, Peters F, et al. Melioidosis in Africa: time to raise awareness and build capacity for its detection, diagnosis, and treatment. Am J Trop Med Hyg 2022; 106:394–397.
Mabayoje DA, Kenna DTD, Dance DAB, NicFhogartaigh C. Melioidosis manifesting as chronic femoral osteomyelitis in patient from Ghana. Emerg Infect Dis 2022; 28:201–204.
Oduro G, Robberts FJL, Dartey PKA, et al. On the environmental presence of Burkholderia pseudomallei in South-Central Ghana. Appl Environ Microbiol 2022; 88:e0060022.
Frickmann H, Poppert S. No hints for abundance of Bacillus anthracis and Burkholderia pseudomallei in 100 environmental samples from Cameroon. Europ J Microbiol Immunol 2021; 11:57–61.
Jayasinghearachchi HS, Francis VR, Sathkumara HD, et al. Nonclonal Burkholderia pseudomallei population in melioidosis case cluster, Sri Lanka. Emerg Infect Dis 2021; 27:2955–2957.
Jayasinghearachchi HS, Corea EM, Jayaratne KI, et al. Biogeography and genetic diversity of clinical isolates of Burkholderia pseudomallei in Sri Lanka. PLoS Negl Trop Dis 2021; 15:e0009917.
Ganesan V, Murugan M, Sundaramurthy R, Soundaram GV. Melioidosis in a tertiary care center from South India: a 5-year experience. Indian J Crit Care Med 2021; 25:327–330.
Menon R, Baby P, Kumar VA, et al. Risk factors for mortality in melioidosis: a single-centre, 10-year retrospective cohort study. Sci World J 2021; 2021: doi: 10.1155/2021/8154810.
doi: 10.1155/2021/8154810
Vinayan S, Bhat UP. Clinical, epidemiological and microbiological profile of a potentially pathogenic environmental saprophyte, Burkholderia pseudomallei ; at a tertiary care hospital in coastal India. J Pure Appl Microbiol 2022; doi: 10.22207/JPAM.16.1.09.
doi: 10.22207/JPAM.16.1.09
Purushotham P, Mohanty S, Chappity P, et al. Identification and characterization of Burkholderia pseudomallei from localized pyogenic infections in Eastern India: a clinico-microbiological study. Am J Trop Med Hyg 2021; 104:1252–1259.
Shaw T, Assig K, Tellapragada C, et al. Environmental factors associated with soil prevalence of the melioidosis pathogen Burkholderia pseudomallei : a longitudinal seasonal study from South West India. Frontiers Microbiol 2022; 13:902996.
Barai L, Saha MR, Rahman T, et al. Trends in laboratory detection of Burkholderia pseudomallei and their antibiotic susceptibility pattern from clinical samples over twenty one years from 2001 to 2021 in a tertiary care hospital of Bangladesh. Bangladesh J Med Microbiol 2021; 15:8–14.
Mohapatra PR, Mishra B. Burden of melioidosis in India and South Asia: challenges and ways forward. Lancet 2022; 2:100004.
Gee JE, Gulvik CA, Castelo-Branco D, et al. Genomic diversity of Burkholderia pseudomallei in Ceara, Brazil. mSphere 2021; 6:e01259–e1320.
Duarte C, Montufar F, Moreno J, et al. Genomic diversity of Burkholderia pseudomallei isolates, Colombia. Emerg Infect Dis 2021; 27:655–658.
Lima RXR, Rolim DB. Melioidosis in children, Brazil, 1989-2019. Emerg Infect Dis 2021; 27:1705–1708.
Cossaboom CM, Marinova-Petkova A, Strysko J, et al. Melioidosis in a resident of Texas with no recent travel history, United States. Emerg Infect Dis 2020; 26:1295–1299.
Gee JE, Bower WA, Kunkel A, Petras J, et al. Multistate outbreak of melioidosis associated with imported aromatherapy spray. New Engl J Med 2022; 386:861–868.
Gulati U, Nanduri AC, Juneja P, et al. Case report: a fatal case of latent melioidosis activated by COVID-19. Am J Trop Med Hyg 2022; 106:1170–1172.
Gupta N, Bhat SN, Reddysetti S, et al. Osteoarticular melioidosis: a retrospective cohort study of a neglected disease. Infez Med 2021; 29:574–582.
Tan WF, Lee HG. Concurrent influenza A and pulmonary melioidosis in pregnancy. Med J Malaysia 2021; 76:245–247.
Gora H, Hasan T, Smith S, et al. Melioidosis of the central nervous system; impact of the bimABm allele on patient presentation and outcome. Clin Infect Dis 2022; ePub ahead of print. doi:10.1093/cid/ciac111.
doi: 10.1093/cid/ciac111
Burnard D, Bauer M, Falconer C, et al. Clinical Burkholderia pseudomallei isolates from Queensland carry diverse bimABm genes that are associated with central nervous system disease and are phylogenomically distinct from other Australian strains. PLoS Negl Trop Dis 2022; 16:e0009482.
Dawson P, Duwell MM, Elrod MG, et al. Human melioidosis caused by novel transmission of Burkholderia pseudomallei from freshwater home aquarium, United States. Emerg Infect Dis 2021; 27:3030–3035.
Somayaji R, Hantrakun V, Teparrukkul P, et al. Comparative clinical characteristics and outcomes of patients with community acquired bacteremia caused by Escherichia coli , Burkholderia pseudomallei and Staphylococcus aureus : a prospective observational study (Ubon-sepsis). PLoS Negl Trop Dis 2021; 15:e0009704.
Chewapreecha C, Pensar J, Chattagul S, et al. Co-evolutionary signals identify Burkholderia pseudomallei survival strategies in a hostile environment. Molecular Biol Evol 2022; 39:7.
Swe MMM, Win MM, Cohen J, et al. Geographical distribution of Burkholderia pseudomallei in soil in Myanmar. PLoS Negl Trop Dis 2021; 15:e0009372.
Warrell CE, Phyo AP, Win MM, et al. Observational study of adult respiratory infections in primary care clinics in Myanmar: understanding the burden of melioidosis, tuberculosis and other infections not covered by empirical treatment regimes. Trans R Soc Trop Med Hyg 2021; 115:914–921.
Chandna A, Bonhoeffer M, Miliya T, et al. Improving treatment and outcomes for melioidosis in children, Northern Cambodia, 2009-2018. Emerg Infect Dis 2021; 27:1169–1172.
Mardhiah K, Wan-Arfah N, Naing NN, et al. The Cox model of predicting mortality among melioidosis patients in Northern Malaysia: a retrospective study. Medicine (Baltimore) 2021; 100:e26160.
Sia TLL, Mohan A, Ooi MH, et al. Epidemiological and clinical characteristics of melioidosis caused by gentamicin-susceptible Burkholderia pseudomallei in Sarawak, Malaysia. Open Forum Infect Dis 2021; 8:ofab460.
Liechti N, Zimmermann RE, Zopfi J, et al. Whole-genome assemblies of 16 Burkholderia pseudomallei isolates from rivers in Laos. Microbiol Resour Announc 2021; 10:e01226-20.
Pongmala K, Pierret A, Oliva P, et al. Distribution of Burkholderia pseudomallei within a 300-cm deep soil profile: implications for environmental sampling. Sci Rep 2022; 12:8674.
Rachlin A, Luangraj M, Kaestli M, et al. Using land runoff to survey the distribution and genetic diversity of Burkholderia pseudomallei in Vientiane, Laos. Appl Environ Microbiol 2021; 87:e02112–e2120.
Smith S, Horne P, Rubenach S, et al. Increased incidence of melioidosis in Far North Queensland, Queensland, Australia, 1998–2019. Emerg Infect Dis 2021; 27:3119–3123.
Hanson J, Smith S, Stewart J, et al. Melioidosis-a disease of socioeconomic disadvantage. PLoS Negl Trop Dis 2021; 15:e0009544.
Fairhead LJ, Smith S, Sim BZ. The seasonality of infections in tropical Far North Queensland, Australia: a 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens. PLoS Glob Public Health 2022; 2:e0000506.
Gassiep I, Ganeshalingam V, Chatfield MD, et al. The epidemiology of melioidosis in Townsville, Australia. Trans R Soc Trop Med Hyg 2022; 328–335.
Currie BJ, Mayo M, Ward LM, et al. The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. Lancet Infect Dis 2021; 21:1737–1746.
Meumann EM, Kaestli M, Mayo M, et al. Emergence of Burkholderia pseudomalle i sequence type 562, Northern Australia. Emerg Infect Dis 2021; 27:1057–1067.
Webb JR, Mayo M, Rachlin A, et al. Genomic epidemiology links Burkholderia pseudomallei from individual human cases to B. pseudomallei from targeted environmental sampling in Northern Australia. J Clin Microbiol 2022; 60:e0164821.
Tran QTL, Phan PH, Bui LNH, et al. Child melioidosis deaths caused by Burkholderia pseudomallei -contaminated borehole water, Vietnam, 2019. Emerg Infect Dis 2022; 28: doi: 10.3201/eid2808.220113.
doi: 10.3201/eid2808.220113
Bhaskaran P, Prasad V, Gopinathan A, et al. Burkholderia pseudomallei in environment of adolescent siblings with melioidosis, Kerala, India, 2019. Emerg Infect Dis 2022; 28:1246–1249.
Watthanaworawit W, Roberts T, Hopkins J, et al. A multicountry study using MALDI-TOF mass spectrometry for rapid identification of Burkholderia pseudomallei . BMC Microbiol 2021; 21:213.
Gassiep I, Bauer MJ, Page M, et al. Comparative evaluation of Panther Fusion and real-time PCR for detection of Burkholderia pseudomallei in spiked human blood. Access Microbiol 2022; 4: doi: 10.1099/acmi.0.000333.
doi: 10.1099/acmi.0.000333
Gassiep I, Burnard D, Bauer MJ, et al. Diagnosis of melioidosis: the role of molecular techniques. Future Microbiol 2021; 16:271–288.
Fairley L, Smith S, Maisrikrod S, Henning L. Systematic review and meta-analysis of diagnostic tests for diagnosis of melioidosis. Acta Trop 2021; 214:105784.
Selvam K, Khalid MF, Mustaffa KMF, et al. BipD of Burkholderia pseudomallei : structure, functions, and detection methods. Microorganisms 2021; 9:711.
Amornchai P, Hantrakun V, Wongsuvan G, et al. Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis. PLoS Negl Trop Dis 2021; 15:e0009840.
Wajanarogana S, Taylor WRJ, Kritsiriwuthinan K. Enhanced serodiagnosis of melioidosis by indirect ELISA using the chimeric protein rGroEL-FLAG300 as an antigen. BMC Infect Dis 2022; 22:387.
Radhakrishnan DA, Behera DB, Mishra DB, et al. Clinico-microbiological description and evaluation of rapid lateral flow immunoassay and PCR for detection of Burkholderia pseudomallei from patients hospitalized with sepsis and pneumonia: a twenty-one months study from Odisha, India. Acta Trop 2021; 221:105994.
Currie BJ, Woerle C, Mayo M, et al. What is the role of lateral flow immunoassay for the diagnosis of melioidosis? Open Forum Infect Dis 2022; 9:ofac149.
Muangsombut V, Withatanung P, Chantratita N, et al. Development of a bacteriophage tail fiber-based latex agglutination assay for rapid clinical screening of Burkholderia pseudomallei . Appl Environ Microbiol 2021; 87: doi: 10.1128/AEM.03019-20.
doi: 10.1128/AEM.03019-20
Sullivan RP, Marshall CS, Anstey NM, et al. 2020 Review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl Trop Dis 2020; 14:e0008659.
Fen Hii S, Tandhavanant S, Phunpang R, et al. Antibiotic susceptibility of clinical Burkholderia pseudomallei isolates in northeast Thailand during 2015–2018 and the genomic characterization of beta-lactam-resistant isolates. Antimicrob Agents Chemother 2021; 65:e02230–e2320.
Bugrysheva JV, Lascols C, McLaughlin HP, et al. Antimicrobial susceptibility of Western Hemisphere isolates of Burkholderia pseudomallei : phenotypic and genomic analyses. Microb Drug Resist 2021.
Somprasong N, Hall CM, Webb JR, et al. Burkholderia ubonensis high-level tetracycline resistance Is due to efflux pump synergy involving a novel TetA (64) resistance determinant. Antimicrob Agents Chemother 2021; 65:e01767–e1820.
Somprasong N, Yi J, Hall CM, et al. Conservation of resistance-nodulation-cell division efflux pump-mediated antibiotic resistance in Burkholderia cepacia complex and Burkholderia pseudomallei complex species. Antimicrob Agents Chemother 2021; 65:e0092021.
Dance DAB, Wuthiekanun V, Baird RW, et al. Interpreting Burkholderia pseudomallei disc diffusion susceptibility test results by the EUCAST method. Clin Microbiol Infect 2021; 27:827–829.
Burnard D, Robertson G, Henderson A, et al. Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin. Antimicrob Agents Chemother 2021; 65:e00685–e00720.
Thammawithan S, Talodthaisong C, Srichaiyapol O, et al. Andrographolide stabilized-silver nanoparticles overcome ceftazidime-resistant Burkholderia pseudomallei : study of antimicrobial activity and mode of action. Sci Rep 2022; 12:10701.
Malawong S, Thammawithan S, Sirithongsuk P, et al. Silver nanoparticles enhance antimicrobial efficacy of antibiotics and restore that efficacy against the melioidosis pathogen. Antibiotics 2021; 10:839.
Petit GA, Mohanty B, McMahon RM, et al. Identification and characterization of two drug-like fragments that bind to the same cryptic binding pocket of Burkholderia pseudomallei DsbA. Acta Crystallogr D Struct Biol 2022; 78 (Pt 1):75–90.
Chapartegui-Gonzalez I, Bowser S, Torres AG, Khakhum N. Recent progress in Shigella and Burkholderia pseudomallei vaccines. Pathogens 2021; 10:1353.
Baker SM, Settles EW, Davitt C, et al. Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine. NPJ Vaccines 2021; 6:18.
Grund ME, Soo JC, Cote CK, et al. Thinking outside the bug: targeting outer membrane proteins for Burkholderia vaccines. Cells 2021; 10:25.
Grund ME, Kramarska E, Choi SJ, et al. Predictive and experimental immunogenicity of Burkholderia collagen-like protein 8-derived antigens. Vaccines 2021; 9:1219.
Tomas-Cortazar J, Bossi L, Quinn C, et al. BpOmpW antigen stimulates the necessary protective T-cell responses against melioidosis. Front Immunol 2021; 12:767359.
Khakhum N, Bharaj P, Walker DH, et al. Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines. NPJ Vaccines 2021; 6:72.
Reddi D, Durant L, Bernardo D, et al. In vitro priming of human T cells by dendritic cells provides a screening tool for candidate vaccines for Burkholderia pseudomallei . Vaccines 2021; 9:22.
Savelkoel J, Dance DAB, Currie BJ, et al. A call to action: time to recognise melioidosis as a neglected tropical disease. Lancet Infect Dis 2022; 22:e176–e182.